Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML1942

Sigma-Aldrich

Drotaverine hydrochloride

≥95% (HPLC), powder, PDE inhibitor

Synonym(s):

1-[(3,4-Diethoxyphenyl)methylene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, 3′,4′,6,7-Tetraethoxy-1-benzylidene-1,2,3,4-tetrahydroisoquinoline hydrochloride, Drotaverin hydrochloride, Tetraspasmin-Lefa

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H31NO4 · HCl
CAS Number:
985-12-6
Molecular Weight:
433.97
MDL number:
MFCD00347721
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Drotaverine hydrochloride, ≥95% (HPLC)

Quality Level

100

Assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

CCOC1=CC=C(/C=C2C3=C(CCN/2)C=C(OCC)C(OCC)=C3)C=C1OCC.[H]Cl

InChI

1S/C24H31NO4.ClH/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20;/h9-10,13-16,25H,5-8,11-12H2,1-4H3;1H/b20-13-;

InChI key

JBFLYOLJRKJYNV-MASIZSFYSA-N

Biochem/physiol Actions

Drotaverine (Drotaverin) is an isoquinoline-based PDE4-selective phosphodiesterase (PDE) inhibitor and an L-type voltage-dependent (voltage-operated) calcium channel (L-VDCC or L-VOCC) blocker that exhibits in vivo antispasmodic efficacy without anticholinergic effects.
It is a benzylisoquinoline derivative. Drotaverine acts as a smooth muscle relaxant.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zoltán Patai et al.
The Journal of pharmacology and experimental therapeutics, 359(3), 442-451 (2016-10-16)
Drotaverine is considered an inhibitor of cyclic-3',5'-nucleotide-phophodiesterase (PDE) enzymes; however, published receptor binding data also support the potential L-type voltage- operated calcium channel (L-VOCC) blocking effect of drotaverine. Hence, in this work, we focus on the potential L-VOCC blocking effect
A G Stepaniuk et al.
Eksperimental'naia i klinicheskaia farmakologiia, 61(4), 17-19 (1998-10-23)
The study was conducted on experimental models of pain sense induced in mice by exposure to thermic or chemical factors and in rats by exposure to electric factors. Nitrosorbide and no-spa possess a dose-dependent analgesic effect. Both drugs excelled analgin
Corradini D, et al.
Handbook of HPLC (2011)
Zsuzsanna Tömösközi et al.
European journal of pharmacology, 449(1-2), 55-60 (2002-08-07)
The effect of the isoquinoline derivative, drotaverine on the specific binding of [(3)H]nitrendipine and [(3)H]diltiazem to pregnant rat uterine membranes was examined. Drotaverine inhibited the specific [(3)H]nitrendipine and [(3)H]diltiazem bindings with IC(50) values of 5.6 and 2.6 microM, respectively. Saturation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service